Abstract 4144
Background
Lung adenosquamous carcinomas (ASC) are morphologically mixed tumors that contain adenocarcinomas component (ACC) and squamous cell carcinomas component (SCCC). However, the genomic profile and immune microenvironment of each component remain unclear.
Methods
ACC and SCCC in ASC (n = 25) were validated by immunohistochemistry and obtained separately by means of laser capture microdissection. Gene panel and T cell receptor (TCR) repertoire sequencing were performed in both components. 578 adenocarcinomas (AC) and 82 squamous cell carcinomas (SCC) were also included for comparison with ASC.
Results
Of 19 paired samples, two components in 94.7% cases had identical gene mutations. The most frequency mutated genes in trunk were EGFR (77.2%), TP53 (44.4%), MDM2 (16.7%), BRD4 (11.1%), CDK4 (11.1%), ERBB2 (11.1%), FAT1 (11.1%) and SMARCA4 (11.1%). Interestingly, the genomic profiles were different when comparing ACC with SCCC, ACC with AC and SCCC with SCC, respectively. MAP3K1 (15% vs. 4.6%) and NF1(15% vs. 4.6%) mutated more frequent in ACC (n = 20) when compared with SCCC (n = 22), while ARAF (13.6% vs. 0%), KEAP1 (13.6% vs. 0%), ALK (13.6% vs. 5%) and PIK3CA (13.6% vs. 5%) in SCCC when compared with ACC. KRAS (11.1%) and APC (7.1%) were observed in AC samples (n = 578), but not in ACC. CDKN2A (24.4%) was exclusive in SCC samples (n = 82) but not in SCCC. Moreover, mutation frequency of EGFR was much higher in SCCC compared with SCC (68.2% vs. 20.7%). The TCR repertoire of two components were markedly different from each other, 57.1% (12/21) paired samples exhibited extremely low level in Morisita-Horn overlap (range from 0 -0.194, mean: 0.09). In addition, TCR clonotype was found in a strong positive correlation with CA125 (p = 0.017, r = 0.70, n = 11) in ACC and with NSE (p = 0.006, r = 0.80, n = 10) in SCCC, respectively.
Conclusions
Our data support the hypothesis that ACC and SCCC in ASC come from the same origin. Diverse genomic profile were exhibited between ACC and SCCC, AC and ACC and SCC and SCCC, which indicated ASC was an unique pathological subtype. TCR repertoire is also distinct in two components in line with the results of genomic profile. Limited by a small number of samples, our study is still ongoing for validation these findings.
Clinical trial identification
Legal entity responsible for the study
Fujian Cancer Hospital.
Funding
Fujian Provincial health systemic youth backbone training projects [grant number 2015-ZQN-ZD-9].
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3819 - Could plasma EBV DNA kinetics predict long-term disease-free survival in metastatic nasopharyngeal carcinoma?
Presenter: LIU guoying
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
5658 - Predictive and Pharmacodynamic Biomarkers Associated with Phase II, selective and orally bioavailable AXL Inhibitor Bemcentinib Across Multiple Clinical Trials
Presenter: Bob Holt
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
1120 - Identification and Validation of a 23-Gene Expression Signature for Subtype Classification of Medulloblastoma
Presenter: Qinghua Xu
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
2122 - Phase I Study of CC-90011 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
Presenter: Antoine Hollebecque
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
Slides
5050 - Lack of efficiency of Precision Oncology with target-based investigational treatments for patients in Early Phase clinical trials based on pre-screened molecular alterations
Presenter: Bernard Doger de Spéville
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
Poster Discussion session - Translational research 2 - Invited Discussant 62PD, 63PD, 64PD, 1832PD and 1833PD
Presenter: Giampaolo Tortora
Session: Poster Discussion session - Translational research 2
Resources:
Slides
Webcast
1375 - High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4
Presenter: Brandon Higgs
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
3857 - Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low
Presenter: Mohamed Salem
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
1969 - Representative Sequencing: profiling extreme tumor diversity
Presenter: Kevin Litchfield
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
2302 - Characterization through whole exome sequencing of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced non-small lung cancer (NSCLC)
Presenter: Jose Luis Perez Gracia
Session: Poster Discussion session - Translational research 2
Resources:
Abstract